173026-23-8

Basic information

• Product Name: 1-(2-Bromophenyl)-1-methylethylamine
• Synonyms: 1-(2-BROMOPHENYL)-1-METHYLETHYLAMINE;1-(1-Amino-1-methylethyl)-2-bromobenzene;BenzeneMethanaMine, 2-broMo-a,a-diMethyl-;2-(2-broMophenyl)propan-2-aMine
• CAS NO: 173026-23-8
• Molecular Formula: C₉H₁₂BrN
• Molecular Weight: 214.1
• Mol File: 173026-23-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 255 °C
• Flash Point: 108 °C
• Appearance: /
• Density: 1.342
• Vapor Pressure: 0.0164mmHg at 25°C
• Refractive Index: 1.555
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 1-(2-Bromophenyl)-1-methylethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Bromophenyl)-1-methylethylamine(173026-23-8)
• EPA Substance Registry System: 1-(2-Bromophenyl)-1-methylethylamine(173026-23-8)

Safety Data

• Hazardous Substances Data: 173026-23-8(Hazardous Substances Data)

Usage

General Description

1-(2-Bromophenyl)-1-methylethylamine, also known as alpha-bromo-4-methylbenzylamine, is a chemical compound with the formula C9H12BrN. It is a colorless to pale yellow liquid with a faint amine odor. 1-(2-Bromophenyl)-1-methylethylamine is primarily used as an intermediate in the manufacture of pharmaceuticals, agrochemicals, and other organic compounds. It is also known to have some potential applications in organic synthesis due to its structural properties. Additionally, 1-(2-Bromophenyl)-1-methylethylamine is classified as a hazardous substance and should be handled and stored with care to prevent exposure and environmental contamination.

InChI:InChI=1/C9H12BrN/c1-9(2,11)7-5-3-4-6-8(7)10/h3-6H,11H2,1-2H3

Upstream product

• 173026-22-7 2-bromo-α,α-dimethylbenzeneacetamide 
• 57775-06-1 2-(2-bromophenyl)-2-methylpropanenitrile 
• 610-94-6 2-bromobenzoic acid methyl ester 
• 7073-69-0 2-(2-bromophenyl)propanol 
• 2042-37-7 o-cyanobromobenzene 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 245677-32-1 1-bromo-2-[1-(dimethylamino)-1-methylethyl]benzene 

Relevant articles and documents

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Effect of benzylic methyl groups on kinetic basicity of amine ligand in o-boron substituted N,N-dimethylbenzylamines

Rates of the dissociation of the intramolecular B-N coordination bond in two series of phenylborane derivatives, the boronate and diethylborane complexes, with -CHMeNMe2 or -CMe2NMe2 group at the o-position were determined